The study showed the blood glucose control throughout the day and overnight. The latter is a common but serious challenge for children and adults with type 1 diabetes, since blood glucose can drop to dangerously low levels when a person is asleep. The artificial pancreas, so-called closed-loop control, is linked to "all-in-one diabetes".  New England Journal of Medicine using a continuous glucose monitor (CGM) and automatically delivers the hormone insulin when needed using an insulin pump.
The International Diabetes Closed-Loop (iDCL) study involves five separate artificial pancreatic clinical protocols implemented by 10 research centers, including UVA. This six-month study is the third phase in the series of trials.
"This artificial pancreas system has several unique features that improve glucose control beyond what is achievable Using traditional methods, "said Boris Kovatchev, Ph.D., director of the UVA Center for Diabetes Technology. Every morning. "
This iDCL protocol enrolled 168" participants age 14 or older with type 1 diabetes. Control-IQ or sensor-augmented pump (SAP) therapy with a CGM and insulin pump that did not adjust insulin throughout the day. Participants had contact with study staff every two weeks to download and review device data.
The researchers found that the users of the artificial pancreas system were suffering from increased blood glucose levels in the target range of 70 to 180 mg / dL by an average of 2.6 hours per day since the beginning of the trial, while the time in range in the SAP group has remained unchanged over six months. Artificial pancreas users also showed improvements in time spent with high and low blood glucose, hemoglobin A1c, and other measurements related to diabetes control compared to the SAP group. High adherence to device use in both groups and 100% participant retention. During the study, no severe hypoglycemia events occurred in either group.
The Control-IQ technology has been developed by UVA by a team led by Kovatchev with funding support from NIDDK. In the system, the insulin pump is programmed with advanced control algorithms based on a mathematical model that uses the person's glucose monitoring. Tandem Diabetes Care has submitted the results to the U.S.
"Artificial pancreas systems offer the ability to improve the glycemic control system." Said A. Brown, MD, from UVA.
Along with Brown, the co-lead authors of the study were Kovatchev and Roy Beck, "This study in particular demonstrates that MD, Ph.D., from the Jaeb Center for Health Research in Tampa, Fla., Which was the coordinating center for the study.
New device achieves better blood sugar control in young children with type 1 diabetes
Artificial pancreas system better controls blood glucose levels than current technology (2019, October 16)
retrieved 16 October 2019
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is for information purposes only.